TITLE:
Comparison of Strontium Ranelate and Alendronate Sodium Treatment among Post-Menopausal Women
AUTHORS:
Unal Eren, Tuba Eren
KEYWORDS:
Osteoporosis, Menopause, Strontium Ranelate, Alendronate Sodium
JOURNAL NAME:
Open Journal of Obstetrics and Gynecology,
Vol.6 No.2,
February
16,
2016
ABSTRACT: Growing rates of osteoporosis in the whole world is a serious health
problem. As the “expected lifetime” is prolonged, population of elderly women
with chronic diseases who require long-term treatment increases. This study
aimed to compare antiresorptive treatment—that has become a classic treatment
in the light of Canadian Guideline for osteoporosis—with the antiresorptive plus
osteoblastic activity inducing treatment modality. The clinical and laboratory
results of patients treated with a single dose of 2 mg Strontium ranelate
sachet (Protelos ®) or alendronate sodium used weekly 70 mg tablet (Fosamax ®once a week tablet) for 12-months were compared. Treatment compliance has been
questioned. A hundred women in post-menopausal period were included in this
study. Patient satisfaction survey among the group of strontium ranelate was
unsatisfactory. Among patients using alendronate sodium the ease of use in this
sense obtained a rate of 91% satisfaction from patients.